Pfizer Reports Q2 Results, Raises Revenue Guidance, But Takes $4.3B Impairment Charge
PFE is trading near its 52-week low of $23.11 (7.9% above the low).
Summary
Pfizer delivered mixed Q2 results, raising revenue guidance but reaffirming EPS guidance due to a $4.3 billion non-cash impairment charge and acquisition impacts, while also announcing new cost-saving initiatives.
Key Events · Earnings and Guidance · PFE
-
Q2 Financials Reported
Reported Q2 revenues of $15.0 billion, representing 1% operational growth (5% excluding COVID-19 products), and Adjusted Diluted EPS of $0.77.
-
Full-Year Revenue Guidance Raised
Full-year 2026 revenue guidance midpoint raised by $500 million to a range of $60.5-$62.5 billion, primarily due to better-than-expected performance of non-COVID products.
-
Full-Year EPS Guidance Reaffirmed
Full-year 2026 Adjusted Diluted EPS guidance reaffirmed at $2.80-$3.00, absorbing an approximate $0.10 unfavorable impact from the Innovent Biologics, Inc. transaction.
-
$4.3 Billion Intangible Asset Impairment
Recorded a significant non-cash intangible asset impairment charge of $4.3 billion, including $3.8 billion for sigvotatug vedotin (due to unfavorable Phase 3 clinical trial results) and $525 million for Oxbryta (no viable pathway to market).
Analysis · PFE · Life Sciences
Pfizer reported mixed second-quarter results, raising its full-year revenue guidance by $500 million at the midpoint, primarily driven by better-than-expected performance in non-COVID products. However, the company reaffirmed its adjusted EPS guidance, absorbing a $0.10 impact from a recent acquisition and reflecting a significant $4.3 billion non-cash intangible asset impairment charge related to a failed Phase 3 trial and an unviable product pathway. The company also announced additional long-term productivity savings.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 29.6% of the 1615 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PFE was trading at $24.94 on NYSE in the Life Sciences sector, with a market capitalization of approximately $142.7B. The 52-week trading range was $23.11 to $28.75. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.